Carbaglu

Phase 2Small molecule

MMendel Tuchman

Carbaglu is one of 5 small molecule programs targeting Hyperammonemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperammonemiaActive, not recruiting

HyperammonemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Hyperammonemia

#DrugCompanyPhaseTrials

N-Carbamylglutamate

MMendel Tuchman

Phase 3

1 2

Xifaxan

Carbaglu

1 4

TNP-2092

TTenNor Therapeutics (Suzhou) Limited

Phase 2

1 5

Sodium Benzoate

LLiminal BioSciences Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperammonemia1 trial

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Completed·MMendel Tuchman·Phase 2·NCT01599286·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carbaglu. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carbaglu compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carbaglu. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mendel Tuchman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMendel Tuchman

Carbaglu

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperammonemia1 trial

References

Drug Info

Quick Facts

Related News